article · International Journal of Electrochemical Science
The need to determine esomeprazole in pharmaceutical formulations and biological fluids with high accuracy arises to ensure proper dosage and follow-up on patient response. In the present investigation, Glassy Carbon Electrode (GCE) was modified by potentiodynamic electropolymerization of Diaquabis(1,10-phenanthroline copper (II) Iodide ([Cu(H 2 O) 2 P 2 ]I 2 ) on its surface with a fixed number of cycles. Cyclic voltammetry (CV) was used to characterize the voltammetric redox behavior of esomeprazole (ESO) on poly([Cu(H 2 O) 2 P 2 ]I 2 )/GCE and the best reversible oxidative current response has been obtained. On the proposed electrode, the electrochemical activity of the ESO was enhanced at a peak intensity that was around 2.6 times higher than the bare one. The calibration curve for ESO at poly([Cu(H 2 O) 2 P 2 ]I 2 )/GCE has a linear region for a concentration range of 0.01 to 200 µM with the detection limit and limit of quantifications of 28.90 and 95.53, respectively and the associated standard deviation was 0.59%. he current sensor has also been effectively used to detect esomeprazole in clinical fluid samples and pharmaceutical samples in a sensitive and selective approach. The outstanding recovery percentage in the range of 95.97–105.26% in the presence of 50–300% potential interferents indicated an excellent accuracy and selectivity of the proposed sensor towards ESO in the presence of potential interferants. The proposed method is simple, quick, stable, and effective for real sensor applications for esomeprazole sensing in different samples. • The current study involved the modification of Glassy Carbon Electrode (GCE) by electropolymerizing [Cu(H 2 O) 2 P 2 ]I 2 on its surface. • Cyclic voltammetry was used to characterize esomeprazole's redox behavior on GCE. • The electrode's electrochemical activity was enhanced, with a peak intensity 2.6 times higher than the bare electrode. • The sensor was successfully applied for sensitive and selective esomeprazole determination in pharmaceutical and clinical samples, with an outstanding recovery percentage of 95.97–105.26% in potential interferents.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.ijoes.2024.100837
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.